The U.S. Food and Drug Administration (FDA) has been flooded with complaints recently over drug shortages, with a large percentage of the grievances coming from patients with attention deficit hyperactivity disorder.

According to the New York Times, many have not been able to find pharmacies equipped to fill their prescriptions as manufacturers have been at odds with the Drug Enforcement Administration (DEA). While drugmakers have increased profits in mind, the DEA is reportedly trying to crack down on abuse of ADHD meds, largely by college students.

Unfortunately, those who needs the pills to cope with ADHD are the ones suffering in the end. Many of the medications in the shortage are generic, meaning patients may have to spend far more money than expected to keep the behavioral disorder at bay with brand names like Ritalin and Adderall.

The Times reports that the shortages are expected to continue until the DEA comes up with “manufacturing quotas that are designed to control supplies and thwart abuse.”

“We have reached out to the DEA and told them that there are shortage issues, but the quota issues are outside of our area of responsibility,” Valerie Jensen, associate director of the drug shortage program at the FDA, told the news source.

A representative for the DEA told the source that there is “plenty of supply” for those with ADHD, with the Times confirming that “some high-priced pills are indeed readily available.”